Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy December 17, ...
More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. The FDA has signed off on a label update for ...
To cut synthetic dyes from private-label foods by January 2027 Says 90% of in-house branded foods currently free of such dyes Several major packaged food companies have made similar move Oct 1 ...
Ahmad Khatami, a senior hardline Iranian cleric, has said that President Donald Trump "portrays himself as a madman so that nations will fear him." Khatami ruled out talks with the United States, ...
In his book The Mathematical Universe, mathematician William Dunham wrote of John Venn’s namesake legacy, the Venn diagram, “No one in the long history of mathematics ever became better known for less ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and ...
The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective ...
LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback